Article
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
The lancet. Gastroenterology & hepatology - 1 Aug 2018
Bourlière Marc, Gordon Stuart C, Schiff Eugene R, Tran Tram T, Ravendhran Natarajan, Landis Charles S, Hyland Robert H, Stamm Luisa M, Zhang Jie, Dvory-Sobol Hadas, Subramanian G Mani, Brainard Diana M, McHutchison John G, Serfaty Lawrence, Thompson Alex J, Sepe Thomas E, Curry Michael P, Reddy K Rajender, Manns Michael P
Abstract excerpt
BACKGROUND: Direct-acting antiviral regimens containing NS5A inhibitors are highly effective treatments for chronic hepatitis C virus (HCV) infection, but are not always successful. In the POLARIS-1 phase 3 study, sofosbuvir-velpatasvir-voxilaprevir for 12 weeks was highly effective in the treatment of chronic HCV infection in patients previously treated with a direct-acting antiviral regimen containing an NS5A...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.